MMRGlobal, Inc. (fka MMRF)

[Mr B]

My understanding is this was part of thier BIO as part of a previous merger ( The licensed assets were acquired from the Company's merger with Favrille).
This is for the research and breakthroughs pertaining to a drug.

Per the 8k; http://sec.gov/Archives/edgar/data/1285701/000113626110000355/body8k.htm

On December 21, 2010, MMRGlobal, Inc., a Delaware corporation (the "Company"), entered into a Non-Exclusive License Agreement (the "Agreement") with Celgene Corporation ("Celgene").

Pursuant to the terms of the Agreement, the Company will license to Celgene, on a non-exclusive basis, the use of the Company's clinical and scientific data relating to targeted immunotherapies for cancer and other disease treatments to stimulate a patient's immune response and certain other confidential information.

In consideration for the rights granted under the Agreement, Celgene will pay the Company certain upfront fees and, upon achievement of development milestones, milestone payments in the aggregate amount of approximately $13 million plus any expenses. The Agreement contains customary provisions, as to the term of the Agreement, representations, warranties, and indemnities by each of the Company and Celgene.

The licensed assets were acquired from the Company's merger with Favrille, Inc. in January 2009. In addition to the FavId vaccine data, MMRGlobal retains worldwide intellectual property rights to numerous additional biotech assets including international patents and anti-CD20 monoclonal antibodies.